Xiaoping Jin
Kelun Group (China) · 94 works · 3,616 citations · h-index 21
Top works
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
- Generalized Hierarchical Multivariate CAR Models for Areal Data
- Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.
- Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
- Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.
- Order-Free Co-Regionalized Areal Data Models with Application to Multiple-Disease Mapping
- Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
- Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma
- Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes
- Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
- Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma
- Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer
- Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in patients with advanced solid tumors.
- Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients
- Colesevelam Hydrochloride to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study
- Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients.
- Low Serum Vitamin D Is Associated with Anti-Thyroid-Globulin Antibody in Female Individuals
- Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.